Tags

Type your tag names separated by a space and hit enter

Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization?
Clin Exp Allergy. 2013 Sep; 43(9):1048-57.CE

Abstract

BACKGROUND

The role of probiotics in prevention of allergic disease is still not clear; efficacy may depend on the timing, dose, duration, and specific probiotic used. Using a double-blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high-risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation from birth until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 10(9) cfu/day) halved the cumulative prevalence of eczema at 2 and 4 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 × 10(9) cfu/day) had no significant effect.

OBJECTIVE

To determine whether differences in effects of HN001 and HN019 on eczema persist to age 6 years, and to investigate effects on sensitization.

METHODS

Standard procedures were used to assess eczema (The UK Working Party's Criteria), eczema severity (SCORAD), atopic sensitization [skin prick tests (SPT), total and specific IgE] and standard questions used for asthma, wheeze, and rhinoconjunctivitis.

RESULTS

HN001 was associated with significantly lower cumulative prevalence of eczema (HR = 0.56, 95% CI 0.39-0.80), SCORAD ≥ 10 (HR = 0.69, 0.49-0.98) and SPT sensitization (HR = 0.69, 95% CI 0.48-0.99). The point prevalence of eczema (RR = 0.66, 95% CI 0.44-1.00), SCORAD ≥ 10 (RR = 0.62, 95% CI 0.38-1.01) and SPT sensitization (RR = 0.72, 95% CI 0.53-1.00) were also reduced among children taking HN001. HN019 had no significant effect on any outcome.

CONCLUSION AND CLINICAL RELEVANCE

This study provides evidence for the efficacy of the probiotic L. rhamnosus HN001 in preventing the development of eczema and possibly also atopic sensitization in high risk infants to age 6 years. The absence of a similar effect for HN019 indicates that benefits may be species specific.

Authors+Show Affiliations

Wellington Asthma Research Group, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. kristin.wickens@otago.ac.nzNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23957340

Citation

Wickens, K, et al. "Early Supplementation With Lactobacillus Rhamnosus HN001 Reduces Eczema Prevalence to 6 Years: Does It Also Reduce Atopic Sensitization?" Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, vol. 43, no. 9, 2013, pp. 1048-57.
Wickens K, Stanley TV, Mitchell EA, et al. Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clin Exp Allergy. 2013;43(9):1048-57.
Wickens, K., Stanley, T. V., Mitchell, E. A., Barthow, C., Fitzharris, P., Purdie, G., Siebers, R., Black, P. N., & Crane, J. (2013). Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology, 43(9), 1048-57. https://doi.org/10.1111/cea.12154
Wickens K, et al. Early Supplementation With Lactobacillus Rhamnosus HN001 Reduces Eczema Prevalence to 6 Years: Does It Also Reduce Atopic Sensitization. Clin Exp Allergy. 2013;43(9):1048-57. PubMed PMID: 23957340.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Early supplementation with Lactobacillus rhamnosus HN001 reduces eczema prevalence to 6 years: does it also reduce atopic sensitization? AU - Wickens,K, AU - Stanley,T V, AU - Mitchell,E A, AU - Barthow,C, AU - Fitzharris,P, AU - Purdie,G, AU - Siebers,R, AU - Black,P N, AU - Crane,J, PY - 2013/01/21/received PY - 2013/04/25/revised PY - 2013/06/02/accepted PY - 2013/8/21/entrez PY - 2013/8/21/pubmed PY - 2014/5/20/medline KW - Bifidobacterium animalis subsp lactis HN019 KW - Lactobacillus rhamnosus HN001 KW - asthma KW - atopic sensitization KW - eczema KW - paediatrics KW - probiotics KW - randomized controlled trial KW - rhinoconjunctivitis KW - wheeze SP - 1048 EP - 57 JF - Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology JO - Clin. Exp. Allergy VL - 43 IS - 9 N2 - BACKGROUND: The role of probiotics in prevention of allergic disease is still not clear; efficacy may depend on the timing, dose, duration, and specific probiotic used. Using a double-blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high-risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation from birth until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 10(9) cfu/day) halved the cumulative prevalence of eczema at 2 and 4 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 × 10(9) cfu/day) had no significant effect. OBJECTIVE: To determine whether differences in effects of HN001 and HN019 on eczema persist to age 6 years, and to investigate effects on sensitization. METHODS: Standard procedures were used to assess eczema (The UK Working Party's Criteria), eczema severity (SCORAD), atopic sensitization [skin prick tests (SPT), total and specific IgE] and standard questions used for asthma, wheeze, and rhinoconjunctivitis. RESULTS: HN001 was associated with significantly lower cumulative prevalence of eczema (HR = 0.56, 95% CI 0.39-0.80), SCORAD ≥ 10 (HR = 0.69, 0.49-0.98) and SPT sensitization (HR = 0.69, 95% CI 0.48-0.99). The point prevalence of eczema (RR = 0.66, 95% CI 0.44-1.00), SCORAD ≥ 10 (RR = 0.62, 95% CI 0.38-1.01) and SPT sensitization (RR = 0.72, 95% CI 0.53-1.00) were also reduced among children taking HN001. HN019 had no significant effect on any outcome. CONCLUSION AND CLINICAL RELEVANCE: This study provides evidence for the efficacy of the probiotic L. rhamnosus HN001 in preventing the development of eczema and possibly also atopic sensitization in high risk infants to age 6 years. The absence of a similar effect for HN019 indicates that benefits may be species specific. SN - 1365-2222 UR - https://www.unboundmedicine.com/medline/citation/23957340/Early_supplementation_with_Lactobacillus_rhamnosus_HN001_reduces_eczema_prevalence_to_6_years:_does_it_also_reduce_atopic_sensitization L2 - https://doi.org/10.1111/cea.12154 DB - PRIME DP - Unbound Medicine ER -